
Opinion|Videos|February 25, 2025
Data With IL-13– Targeting Agents in Atopic Dermatitis in Clinical Practice
Panelists discuss switching from dupilumab to other IL-13 inhibitors in atopic dermatitis (AD), reviewing real-world data (RWD) on the effectiveness, safety, and patient outcomes associated with these treatments.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you talk about switching from dupilumab and other RWD with IL-13 agents in AD?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Prevalence and Recognition of Hypercortisolism
2
Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes
3
Skin of Color Savvy—A New Generation of Dermatology Leadership, With Umayr Shaikh, MPH
4
Distinguishing CSU From Chronic Inducible Urticaria Subtypes
5

























































































